CN106177474A - 一种具有治疗慢性肝炎功效的金线莲含片 - Google Patents
一种具有治疗慢性肝炎功效的金线莲含片 Download PDFInfo
- Publication number
- CN106177474A CN106177474A CN201610804323.5A CN201610804323A CN106177474A CN 106177474 A CN106177474 A CN 106177474A CN 201610804323 A CN201610804323 A CN 201610804323A CN 106177474 A CN106177474 A CN 106177474A
- Authority
- CN
- China
- Prior art keywords
- parts
- chronic hepatitis
- buccal tablet
- herba
- terminal bud
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 30
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 27
- 206010008909 Chronic Hepatitis Diseases 0.000 title claims abstract description 24
- 239000006189 buccal tablet Substances 0.000 title claims abstract description 24
- 229940046011 buccal tablet Drugs 0.000 title claims abstract description 24
- 241000719837 Anoectochilus Species 0.000 title claims abstract description 21
- 229920002472 Starch Polymers 0.000 claims abstract description 26
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 18
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 18
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims abstract description 14
- 235000019890 Amylum Nutrition 0.000 claims abstract description 13
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019698 starch Nutrition 0.000 claims abstract description 13
- 239000008107 starch Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- 241000411851 herbal medicine Species 0.000 claims description 6
- 239000003390 Chinese drug Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 244000194101 Ginkgo biloba Species 0.000 claims 3
- 241000934230 Anoectochilus roxburghii Species 0.000 claims 1
- 244000247747 Coptis groenlandica Species 0.000 claims 1
- 235000002991 Coptis groenlandica Nutrition 0.000 claims 1
- 240000002853 Nelumbo nucifera Species 0.000 claims 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 235000002789 Panax ginseng Nutrition 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 18
- 241000218628 Ginkgo Species 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 12
- 210000003494 hepatocyte Anatomy 0.000 abstract description 8
- 206010016654 Fibrosis Diseases 0.000 abstract description 3
- 230000004761 fibrosis Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000007923 virulence factor Effects 0.000 abstract description 2
- 239000000304 virulence factor Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 101100256850 Drosophila melanogaster EndoA gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- WJHSRFQBVYHKKL-UHFFFAOYSA-N Oroboside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(C=3C=C(O)C(O)=CC=3)=COC2=C1 WJHSRFQBVYHKKL-UHFFFAOYSA-N 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007881 chronic fibrosis Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种具有治疗慢性肝炎功效的金线莲含片，由以重量份为单位的下列各组分精制而成：金线莲20‑50份，连翘10‑30份，光果甘草根1‑10份，银杏叶1‑3份，独脚金2‑8份，小春花2‑8份，丹参1‑5份，五味子1‑10份，淀粉1‑10份，可压性淀粉0.1‑0.5份，异麦芽糖醇0.1‑1份，滑石粉0.1‑1份。金线莲是我国民间常用保肝中药，本发明将金线莲与连翘、光果甘草跟、银杏叶、独脚金、小春花、丹参、五味子等中药进行复配，可有效减轻致病因子对肝细胞的损害，同时缓解甚至逆转肝细胞纤维化，具有良好的治疗慢性肝炎的效果。
Description
技术领域
本发明涉及治疗慢性肝炎的药物，尤其涉及一种具有治疗慢性肝炎功效的金线莲含片。
背景技术
慢性肝炎是指由不同病因引起的，病程至少持续超过6个月以上的肝脏坏死和炎症，如感染肝炎病毒（乙肝病毒，丙肝病毒），长期饮酒，服用肝毒性药物等。病程呈波动性或持续进行性，如不进行适当的治疗，部分患者可进展为肝硬化。慢性肝炎是一类疾病的统称，病因不同，其临床特点、治疗方法以及预后结局可能有所不同，但都具有肝功能反复波动，迁延不愈；肝组织均有不同程度的坏死和纤维结缔组织增生，呈现慢性纤维化；病情发展的最终阶段均为肝硬化；以及均需要保肝和抗纤维化治疗等特征。
近年来中药已被广泛用于西医结合防治肝病的发生，其护肝功能可能机制有：通过清除自由基防止肝细胞损伤、改善胆红素代谢、促进白蛋白的合成、解除糖元合成障碍、促进糖元合成。
据大量金线莲药理实验研究文献报道，金线莲能直接作用於肝细胞膜，保护肝细胞膜的完整，防止有害物质破坏肝细胞膜，并防止肝细胞之病变成坏死。同时能渗透肝细胞膜，增进肝脏的新陈代谢，使受伤的细胞复活，进而再生，而且又可恢复肝细胞内酵素的机能，增进细胞氧化作用，使肝功能各项检验值恢复正常。
发明内容
本发明的目的在于提供一种具有治疗慢性肝炎功效的金线莲含片，适合慢性肝炎患者服用。
为实现上述目的，本发明采用如下技术方案：
一种具有治疗慢性肝炎功效的金线莲含片，包括以下重量份原料：金线莲20-50份，连翘10-30份，光果甘草根1-10份，银杏叶1-3份，独脚金2-8份，小春花2-8份，丹参1-5份，五味子1-10份，淀粉1-10份，可压性淀粉0.1-0.5份，异麦芽糖醇0.1-1份，滑石粉0.1-1份。
优选的，包括以下重量份原料：金线莲50份，连翘10份，光果甘草根3份，银杏叶3份，独脚金6份，小春花4份，丹参2份，五味子3份，淀粉8份，可压性淀粉0.4份，异麦芽糖醇0.6份，滑石粉0.3份。
一种具有治疗慢性肝炎功效的金线莲含片，其制备方法如下：
（1）按如上重量称取金线莲、连翘、光果甘草根、银杏叶、独脚金、小春花、丹参、五味子等中草药，进行冷冻干燥；
（2）将干燥后的原料进行粉碎；
（3）将粉碎后的原料组分放入中药超微粉碎机粉碎；
（4）将淀粉、可压性淀粉、异麦芽糖醇等原料加入步骤（3）所得混合物中，混合均匀后烘干；
（5）将步骤（4）所得干燥物进行整粒，加入滑石粉进行总混；
（6）将步骤（5）所得颗粒进行压片及得到所述具有治疗慢性肝炎功效的金线莲含片。
金线莲：金线莲是兰科开唇兰属多年生草本植物。是我国传统的珍贵药材，具有保肝、降血糖、降血压、利尿、抗肿瘤等作用，并且无毒副作用，使用安全。在民间较多用其治疗糖尿病、乙型肝炎、高血脂、肿瘤等疾病。其主要成分为糖苷、生物碱、甾体、黄酮、牛磺酸、氨基酸、微量元素等。有研究表明金线莲能直接作用于肝细胞膜，保护肝细胞膜的完整，防止有害物质破坏肝细胞膜，并防止肝细胞之病变性坏死。
连翘：在我国河北、河南、陕西、山西等地，民间常采集连翘嫩叶，经加工制成保健茶饮用。现代药理研究发现，连翘液提取物有抗菌、抗氧化、抗衰老、抗疲劳等作用。
光果甘草根：从光果甘草根部提取的甘草甜素具有广谱的抗病毒活性，能刺激干扰素的产生，使巨噬细胞和自然杀伤细胞的活性增强。
银杏叶：银杏叶具有活血化瘀、通络止痛、敛肺平喘、化浊降脂的作用。
独脚金：平肝消疳、健脾消食、清热利尿。属清热药下属分类的清热泻火药。对腹泻、肝炎有一定的疗效。其含有木犀草素，具有抗纤维化的作用，可以降低肝纤维化程度，降低肝组织中羟脯氨酸、丙二醛的含量以及I型前胶原mRNA的表达。
小春花：小春花为阴地蕨科植物阴地蕨，为民间常用药材，就有清热解毒、平肝熄火、止咳、止血、明目祛翳等功效。民间用于治疗小儿高热惊搐、肺热咳嗽、咳血、百日咳、癫狂、痫疾等病。
丹参：能抑制和减轻急慢性肝损伤时肝细胞变性、坏死以及炎症反应。促进肝细胞的再生及肝功能的恢复，促进肝内的胶原蛋白的降解而具有抗肝纤维化、防止肝硬化的发生的作用。
五味子：对可减轻中毒肝损伤的物质代谢障碍，具有轻度升高肝糖元、减轻干细胞变性，减轻中毒致病因子对肝细胞线粒体和溶酶体的破坏，有促进肝细胞内蛋白质合成的作用。
本发明的优点在于：
本发明将金线莲、连翘、光果甘草根、银杏叶、独脚金、小春花、丹参以及五味子等中草药进行合理配伍，并制成含片的形式，实现了各中草药之间的协同增效作用，含片的服用形式增加了药物的吸收时间，能达到良好的慢性肝炎治疗效果。具体表现为：金线莲、五味子等中药具有保肝作用；光果甘草根具有抗病毒活性，可杀灭病毒；小春花、独脚金等药材含有木犀草苷，具有抗纤维化的作用，可降低肝纤维化程度；而丹参、银杏叶则具有活血化瘀、促进肝细胞再生及肝功能恢复等作用。药物间作用层层递进，协同增效，能达到良好的抗病毒功效。
具体实施方式
实施例1
一种具有治疗慢性肝炎功效的金线莲含片，其特征在于：包括以下重量份原料：金线莲20份，连翘10份，光果甘草根1份，银杏叶1份，独脚金2份，小春花2份，丹参1份，五味子1份，淀粉1份，可压性淀粉0.1份，异麦芽糖醇0.1份，滑石粉0.1份。
其制备方法如下：
（1）按如上重量称取金线莲、连翘、光果甘草根、银杏叶、独脚金、小春花、丹参、五味子等中草药，进行冷冻干燥；
（2）将干燥后的原料进行粉碎；
（3）将粉碎后的原料组分放入中药超微粉碎机粉碎；
（4）将淀粉、可压性淀粉、异麦芽糖醇等原料加入步骤（3）所得混合物中，混合均匀后烘干；
（5）将步骤（4）所得干燥物进行整粒，加入滑石粉进行总混；
（6）将步骤（5）所得颗粒进行压片及得到所述具有治疗慢性肝炎功效的金线莲含片。
实施例2
一种具有治疗慢性肝炎功效的金线莲含片，其特征在于：包括以下重量份原料：金线莲50份，连翘30份，光果甘草根10份，银杏叶3份，独脚金8份，小春花8份，丹参5份，五味子10份，淀粉10份，可压性淀粉0.5份，异麦芽糖醇1份，滑石粉1份。
其制备方法如下：
（1）按如上重量称取金线莲、连翘、光果甘草根、银杏叶、独脚金、小春花、丹参、五味子等中草药，进行冷冻干燥；
（2）将干燥后的原料进行粉碎；
（3）将粉碎后的原料组分放入中药超微粉碎机粉碎；
（4）将淀粉、可压性淀粉、异麦芽糖醇等原料加入步骤（3）所得混合物中，混合均匀后烘干；
（5）将步骤（4）所得干燥物进行整粒，加入滑石粉进行总混；
（6）将步骤（5）所得颗粒进行压片及得到所述具有治疗慢性肝炎功效的金线莲含片。
实施例3
一种具有治疗慢性肝炎功效的金线莲含片，其特征在于：包括以下重量份原料：金线莲50份，连翘10份，光果甘草根3份，银杏叶3份，独脚金6份，小春花4份，丹参2份，五味子3份，淀粉8份，可压性淀粉0.4份，异麦芽糖醇0.6份，滑石粉0.3份。
其制备方法如下：
（1）按如上重量称取金线莲、连翘、光果甘草根、银杏叶、独脚金、小春花、丹参、五味子等中草药，进行冷冻干燥；
（2）将干燥后的原料进行粉碎；
（3）将粉碎后的原料组分放入中药超微粉碎机粉碎；
（4）将淀粉、可压性淀粉、异麦芽糖醇等原料加入步骤（3）所得混合物中，混合均匀后烘干；
（5）将步骤（4）所得干燥物进行整粒，加入滑石粉进行总混；
（6）将步骤（5）所得颗粒进行压片及得到所述具有治疗慢性肝炎功效的金线莲含片。
实施例4
Balb/c小鼠适应性喂养7天后随机分为4组，每组20只：对照组、模型组、金线莲含片组、阳性对照组。模型组、金线莲含片组、阳性对照组均静脉注射刀豆蛋白A诱发肝炎，金线莲含片组所服用金线莲含片如实施例3所示，阳性对照组为水飞蓟阳性对照组（250mg/kg）。每组小鼠连续口服给药14天，正常组和模型组给予等量的生理盐水；最后一次给药后禁食12h，称量体重测定AST以及ALT值并取肝脏计算肝指数。
肝比重的计算公式如下：
肝比重=[肝重/体重]×100%
表1 各试验组小鼠存活率及肝比重值
表2 各试验组小鼠AST和ALT比较
以上所述仅为本发明的较佳实施例，凡依本发明申请专利范围所做的均等变化与修饰，皆应属本发明的涵盖范围。
Claims (3)
1.一种具有治疗慢性肝炎功效的金线莲含片，其特征在于：包括以下重量份原料：金线莲20-50份，连翘10-30份，光果甘草根1-10份，银杏叶1-3份，独脚金2-8份，小春花2-8份，丹参1-5份，五味子1-10份，淀粉1-10份，可压性淀粉0.1-0.5份，异麦芽糖醇0.1-1份，滑石粉0.1-1份。
2.如权利要求1所述的一种具有治疗慢性肝炎功效的金线莲含片，其特征在于：包括以下重量份原料：金线莲50份，连翘10份，光果甘草根3份，银杏叶3份，独脚金6份，小春花4份，丹参2份，五味子3份，淀粉8份，可压性淀粉0.4份，异麦芽糖醇0.6份，滑石粉0.3份。
3.如权利要求1或2所述的一种具有治疗慢性肝炎功效的金线莲含片，其特征在于：金线莲含片的制备方法如下：
（1）按如上重量称取金线莲、连翘、光果甘草根、银杏叶、独脚金、小春花、丹参、五味子等中草药，进行冷冻干燥；
（2）将干燥后的原料进行粉碎；
（3）将粉碎后的原料组分放入中药超微粉碎机粉碎；
（4）将淀粉、可压性淀粉、异麦芽糖醇等原料加入步骤（3）所得混合物中，混合均匀后烘干；
（5）将步骤（4）所得干燥物进行整粒，加入滑石粉进行总混；
（6）将步骤（5）所得颗粒进行压片及得到所述具有治疗慢性肝炎功效的金线莲含片。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610804323.5A CN106177474A (zh) | 2016-09-06 | 2016-09-06 | 一种具有治疗慢性肝炎功效的金线莲含片 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610804323.5A CN106177474A (zh) | 2016-09-06 | 2016-09-06 | 一种具有治疗慢性肝炎功效的金线莲含片 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106177474A true CN106177474A (zh) | 2016-12-07 |
Family
ID=58066439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610804323.5A Pending CN106177474A (zh) | 2016-09-06 | 2016-09-06 | 一种具有治疗慢性肝炎功效的金线莲含片 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106177474A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772253A (zh) * | 2005-09-27 | 2006-05-17 | 韩云超 | 一种治疗慢性乙型肝炎的中药 |
| CN102697748A (zh) * | 2012-06-21 | 2012-10-03 | 厦门加晟生物科技有限公司 | 一种金线莲含片及其制备方法 |
| CN103127389A (zh) * | 2012-12-26 | 2013-06-05 | 福建省金草生物集团有限公司 | 一种复方保肝金线莲超微粉及其加工方法 |
-
2016
- 2016-09-06 CN CN201610804323.5A patent/CN106177474A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772253A (zh) * | 2005-09-27 | 2006-05-17 | 韩云超 | 一种治疗慢性乙型肝炎的中药 |
| CN102697748A (zh) * | 2012-06-21 | 2012-10-03 | 厦门加晟生物科技有限公司 | 一种金线莲含片及其制备方法 |
| CN103127389A (zh) * | 2012-12-26 | 2013-06-05 | 福建省金草生物集团有限公司 | 一种复方保肝金线莲超微粉及其加工方法 |
| CN103127389B (zh) * | 2012-12-26 | 2014-12-17 | 福建省龙岩市梁野山种业有限公司 | 一种复方保肝金线莲超微粉及其加工方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103070880B (zh) | 白簕多糖在制备治疗糖尿病药物中的应用 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN112569332A (zh) | 小柴胡提取物在治疗病毒性肺炎中的应用 | |
| CN103386022B (zh) | 一种治疗结核性胸膜炎的中药组合物 | |
| CN112675278A (zh) | 润肺止咳、抑制肺部炎症反应的组合物及其制备方法和用途 | |
| CN107773679A (zh) | 一种辅助降血脂、辅助溶解血栓的组合物及其制备工艺 | |
| CN101390970A (zh) | 一种治疗乙肝的中药及其制备方法 | |
| CN109045138A (zh) | 一种辅助治疗痛风的复方芹菜籽片剂及其制备方法 | |
| CN1876167A (zh) | 治疗慢性支气管炎病的药物及其制备方法 | |
| CN104095940B (zh) | 一种治疗痛风的中药组合物 | |
| CN108553584B (zh) | 一种辅助降血糖的组合物及其应用 | |
| CN106177474A (zh) | 一种具有治疗慢性肝炎功效的金线莲含片 | |
| CN101732469B (zh) | 一种中药组合物在制备治疗失音症药物中的应用 | |
| CN107441317A (zh) | 一种用于特禀体质过敏性鼻炎治疗的中药方剂 | |
| CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 | |
| CN104623615A (zh) | 一种治疗哮喘的药物 | |
| CN104208168B (zh) | 一种用于治疗家禽呼吸道感染的复方中药组合物及其制备方法 | |
| CN103880913A (zh) | 一种具有保肝作用的化合物及其应用 | |
| CN108704036A (zh) | 一种治疗痛风的复方中药制剂及其制备方法 | |
| CN106474421B (zh) | 一种治疗结直肠癌的中药组合物及其应用 | |
| CN105561007A (zh) | 一种用于治疗小儿流行性感冒的中药制剂及制备方法 | |
| CN104147245B (zh) | 一种猪毛菜组合物、其制备方法及其在制备减肥降脂药物中的应用 | |
| CN105031364A (zh) | 一种防治风火牙痛的制剂及制备方法 | |
| CN104547695B (zh) | 一种用于治疗三叉神经痛的药物组合物及其应用 | |
| CN103356984B (zh) | 一种防治女性缺铁性贫血的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161207 |